You are here:
Home / Archives for Eli Lilly & Co
Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other tactics. [...]
Filed under Articles · Tagged with Abelcet, activism, activist, Adagen, Alexander Denner, Alkermes, ALKS, AMLN, Amylin Pharmaceuticals, AstraZeneca plc, Avonex, AZN, BIIB, Biogen Idec, biotech, biotechnology, Biotechnology Value Fund, BMY, Bristol-Myers Squibb, Byetta, canfosfamide, Carl Icahn, cetuximab, DellaCamera Capital Management, DepoCyt, Eastbourne Capital Management, Eli Lilly, Eli Lilly & Co, EMIS, Emisphere Technologies, Endo Pharmaceuticals, ENDP, ENZN, Enzon Pharmaceuticals, Erbitux, EXEL, Exelixis, exenatide, Icahn Management, ImClone, interferon beta-1a, interferon beta-1b, LLY, Medarex, MedImmune, medx, multiple sclerosis, NASDAQ Biotechnology Index, NBI, Novartis AG, NVS, Oncaspar, Regeneron Pharmaceuticals, REGN, Richard Mulligan, shareholder activist, Telcyta, Telik, TELK, Third Point LLC
